Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | LSS | P48449 | 2/20 | 0.35 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.31 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19083183 | 0.85 | CYP1A2 (0.42) | CYP1A2MAPTLSSDPP4POLB | |
| SCHEMBL22757296 | 0.85 | CYP1A2 (0.42) | CYP1A2MAPTLSSDPP4POLB | |
| SCHEMBL20953381 | 0.79 | OPRM1 (0.31) | KDM2B | |
| SCHEMBL23920908 | 0.79 | HRH3 (0.35) | HRH3KDM2B | |
| SCHEMBL17715681 | 0.79 | NCF1 (0.44) | DPP4GNAO1KDM2B | |
| SCHEMBL14197719 | 0.78 | SIGMAR1 (0.37) | MAPTDPP4POLB | |
| SCHEMBL23797644 | 0.78 | CYP1A2 (0.47) | CYP1A2MAPTDPP4POLBHPGD | |
| SCHEMBL7706841 | 0.77 | CYP1A2 (0.50) | CYP1A2MAPTDPP4POLBHPGD | |
| SCHEMBL27429858 | 0.77 | UBE2M (0.34) | CYP1A2MAPTHRH3GNAO1KDM2B | |
| SCHEMBL8362610 | 0.76 | OPRM1 (0.34) | DPP4KDM2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190689-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190689-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | PIK3CG, PIK3CD, PIK3CB | CYP1A2 2540/4885MAPT 3007/4885LSS 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.